{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:09:27Z","timestamp":1768000167072,"version":"3.49.0"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although <jats:sc>L<\/jats:sc>\u2010asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05\u201001 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6\u2010mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents. Pediatr Blood Cancer 2012; 59: 925\u2013927. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pbc.24182","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T18:43:19Z","timestamp":1335292999000},"page":"925-927","source":"Crossref","is-referenced-by-count":19,"title":["Asparaginase\u2010associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"59","author":[{"given":"Reid","family":"Merryman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"William J.","family":"Gostic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.253"},{"key":"e_1_2_5_3_2","first-page":"600","article-title":"Incidence and management of asparaginase\u2010associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl M","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1969.tb107492.x"},{"key":"e_1_2_5_5_2","first-page":"196","article-title":"Leukocyte alterations during asparaginase therapy","volume":"121","author":"Kolarz G","year":"1971","journal-title":"Wien Med Wschr"},{"key":"e_1_2_5_6_2","first-page":"52","article-title":"Investigations with L\u2010asparaginase therapy in malignant hematologic diseases","volume":"51","author":"Lorie YI","year":"1973","journal-title":"Klin Med (Moskva)"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5923.81"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-045369"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3180640d54"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401310"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24182","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:31:00Z","timestamp":1696847460000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/pbc.24182"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24182","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]}}}